Vertex Pharmaceuticals will report Q3 results on Nov 2, with focus on whether its non-cystic fibrosis drugs CASGEVY and JOURNAVX meet the $500 million revenue target. Q2 revenue rose 12.4% to $3.33 billion, beating estimates, though adjusted EPS slightly missed. The company recently acquired Crinetics, expanding into rare endocrine diseases, and expects full-year revenue of $13.10-$13.20 billion. Investors will watch CASGEVY infusions and JOURNAVX prescriptions closely, as well as the upcoming renal drug launch and updated guidance including Crinetics' impact.
Vertex Pharmaceuticals holds a substantial market cap of $132.80 billion as of Oct 26, 2026, 21:03 WIB, with a trading volume of 832,628 shares on Pluang. The stock price stands at USD 518.00, down 1.13% on the day. This scale and activity level provide context as investors anticipate the Q3 report focusing on the $500 million revenue target for non-cystic fibrosis drugs.
